VTE Anticoagulation Duration Decision Tool

An Evidence-Based Decision-Analytical Approach to Determine Optimal Duration of Anticoagulation

How to Use This Tool: Select a clinical scenario below, adjust patient parameters based on available evidence and patient preferences, and the tool will calculate treatment thresholds to guide anticoagulation duration decisions. The tool uses a decision-analytical threshold model that integrates VTE recurrence risk, bleeding risk, and patient values/preferences.

Patient & Treatment Parameters

RV < 1: Values VTE prevention more than bleeding. RV > 1: Values bleeding prevention more. RV = 1: Values equally.

Default: 85% (ASH 2020)
Default: 2.17 (ASH 2020)

Clinical Recommendation

VTE Recurrence Risk vs Treatment Thresholds Over Time

Instructions: The thick black line shows VTE recurrence risk without treatment over time. Dashed colored lines show treatment thresholds based on your selected parameters and RV. When VTE risk exceeds the threshold, anticoagulation is indicated. When it falls below, discontinuation may be considered.
VTE Risk (no Rx)
Treatment Threshold

Patient & Treatment Parameters

k = exponential decay constant for VTE risk

RV < 1: Values VTE prevention more than bleeding. RV > 1: Values bleeding prevention more.

Default: 7.5%

Clinical Recommendation

VTE Risk Trajectory & Treatment Thresholds

Instructions: The curves show how VTE risk decays after the travel episode based on travel frequency. The threshold line indicates when anticoagulation can be discontinued.

Patient & Treatment Parameters

Default: 4% (high risk)
Default: 3.5

RV ≤ 0.5: Treatment only if strongly prefers VTE prevention over bleeding.

Default: 85% (ASH 2020)

Clinical Recommendation

VTE Recurrence Risk vs Treatment Thresholds

Key Insight: In high-bleeding-risk PVT patients, anticoagulation is only justified when RV ≤ 0.5 (strong preference for VTE prevention) and only for 1-2 years.[NB change bleeding risk in the Baseline Ann Bleed Risk and RR Bleeding boxes,respectively.]

Threshold Decision Model

The treatment threshold (Trx) is calculated using the following equation:

Trx = RV × [Cumulative Bleeding Risk] / RRR

Decision Rule:
• If VTE Risk (without treatment) > Trx → Anticoagulation is indicated
• If VTE Risk (without treatment) < Trx → Anticoagulation may be discontinued
• Annual reassessment is recommended

Model Parameters & Evidence Sources

VTE Recurrence Risk (Unprovoked): Based on Khan et al. (BMJ 2019) systematic review of 18 RCTs and observational studies (n=7,515): 10.3% at 1yr, 16.0% at 2yr, 25.2% at 5yr, 36.1% at 10yr. Long-term data (20yr) from Kyrle et al. (J Thromb Haemost 2016): 44% cumulative risk.
Relative Risk Reduction (RRR) for VTE: 0.85 (95% CI: 0.77–0.90), high certainty evidence per ASH 2020 VTE Management Guidelines.
Major Bleeding Risk: Baseline risk 0.5% annually (low risk) to 1.5% annually (high risk). Relative Risk for major bleeding with DOACs: 2.17 (95% CI: 1.40–3.35, high certainty), per ASH 2020.
Patient Values & Preferences (RV): Elicited using regret-based approach. RV < 1: Patient values avoiding VTE consequences more than bleeding. RV > 1: Values bleeding prevention more. RV = 1: Values outcomes equally (default).
Travel-Associated VTE: Year 1 recurrence risk ~7.5% (25% lower than unprovoked). Risk decay modeled using exponential function with decay constant k reflecting flight frequency.
Portal Vein Thrombosis in Cirrhosis: Pooled recurrence risk ~24% (CI: 14.7–33.4%) at median 6–48 months follow-up. Elevated bleeding risk 4–7% annually depending on severity. RRI for bleeding: 3.5.

Publication Details

Edit citation below as needed (update after publication in Blood Advances):

Key References

1. Khan F, Rahman A, Carrier M, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019;366:l4363.
2. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Advances. 2020;4(19):4693-4738.
3. Kyrle PA, Kammer M, Eischer L, et al. The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study. J Thromb Haemost. 2016;14(12):2402-2409.
4. MacCallum PK, Ashby D, Hennessy EM, et al. Cumulative flying time and risk of venous thromboembolism. Br J Haematol. 2011;155(5):613-619.
5. Giri S, Singh A, Kolhe K, et al. Natural history of portal vein thrombosis in cirrhosis: A systematic review with meta-analysis. J Gastroenterol Hepatol. 2023;38(10):1710-1717.

This tool provides evidence-based guidance for shared decision-making regarding anticoagulation duration. Clinical judgment and patient-specific factors should always be incorporated into final treatment decisions.

© 2025 Benjamin Djulbegovic, MD, PhD | Medical University of South Carolina